Testing sirolimus for long-term treatment of LAM
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have a confirmed diagnosis of LAM based on ATS/JRS criteria
- You can sign and date informed consent
- You are on treatment now, starting treatment, or considered for mTOR-inhibitor medicines (or you couldn’t tolerate or tried them before without success)
- You can attend at least one regular clinic visit each year
- You can do lung (pulmonary) function testing and are willing to do the breathing tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
Hear when a new Lymphangioleiomyomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.